Navigation Links
Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection

TAMPA, Fla., April 16, 2007 /PRNewswire/ -- Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced today that it has received orphan drug designation from the Food and Drug Administration (FDA) for its anti-viral therapy, ganciclovir, for the treatment of acute herpetic keratitis. The product is currently marketed by Laboratoires Thea in Europe under the brand name of Virgan(R). Sirion licensed the rights to Virgan(R) for the United States from Laboratoires Thea in January 2007.

Orphan drug designation is a special status for diseases or conditions affecting fewer than 200,000 patients in the United States, granted by FDA upon request by a sponsor. Drugs that receive orphan drug designation obtain seven years of marketing exclusivity from the date of drug approval as well as tax credits for clinical trial costs, marketing application filing fee waivers and assistance from the FDA in the drug development process.

"We are pleased to receive orphan drug designation from the FDA for ganciclovir," said Christine Miller, Sirion's Vice President of Regulatory Affairs. "Topical ganciclovir has been available in Europe for the treatment of ocular viral infections for over 10 years. This product has the potential to advance medical treatment of herpes simplex keratitis in the U.S. Herpes simplex keratitis is a leading cause of corneal blindness in the United States."

According to data published in the journal Archives of Ophthalmology, herpes simplex keratitis affects approximately 50,000 people annually in the United States, arising as acute primary disease in 20,000 people and recurrent disease in an additional 28,000.

Adds Barry Butler, Sirion's President and CEO, "Sirion is pleased to be able to offer ophthalmologists an important tool to battle this blinding disease. It is gratifying to know that our work has the potential to help patients preserve their sig
'"/>




Page: 1 2

Related medicine technology :

1. Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:9/23/2014)... Canada , September 23, 2014 ... and lifestyle related disorders and increasing number of foreign ... demand for probiotic in India ... as one of the most high growth potential markets ... concerns among consumers especially among the youth, changing food ...
(Date:9/23/2014)... CORALVILLE, Iowa , Sept. 23, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... received a No Objection Letter (NOL) from Health ... Canada for its lead product candidate ... hydrocodone prodrug in development for acute moderate to ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... a young boy who was given just days to live now looks ... Logan Green of Arizona complained of a ... of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... The Dutch biotech company Skyline Diagnostics B.V. (Skyline) ... (Clavis) disclosed signing a research agreement. Under this agreement, ... individual Acute Myeloid Leukemia (AML) patients that may benefit ... This drug, elacytarabine, is a novel elaidic acid derivative ...
... demonstrate its continued commitment to innovative immunoglobulin (Ig) research, ... is seeking proposals for the next round of Interlaken ... program provides monetary grants and/or product supply to advance medical ... in the treatment of neurological disorders. From the ...
Cached Medicine Technology:Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug elacytarabine 2CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology 2CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology 3
(Date:9/23/2014)... has awarded $10.1 million in supplemental funding to bolster ... of sex in preclinical and clinical studies. , This ... is a catalyst for considering sex as a fundamental ... in preclinical research can obscure key findings related to ... approach will result in greater awareness of the need ...
(Date:9/23/2014)... The Westlake Village sedation dentist ... oral sedation with treatment for new patients. Studies have ... dental anxiety or dental phobia. These common conditions are ... keep patients from seeking desperately needed dental care. , ... and surrounding areas now have an opportunity to manage ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
(Date:9/23/2014)... 23, 2014 Catalent Pharma ... delivery technologies and development solutions for drugs, ... that it had reached an exclusive development ... company, Cingulate Therapeutics (CTx), to support the ... pharmaceutical products for the treatment of Attention ...
(Date:9/23/2014)... losing your job can increase the risk for developing asthma, ... more than 7,000 employed adults in Germany. Between 2009 and ... questions about the respiratory disorder and also on whether they ... More than 100 new cases of asthma were diagnosed among ... study period. The researchers noted that for every 25 ...
Breaking Medicine News(10 mins):Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3Health News:Job Worries Can Raise Asthma Risk, Study Says 2
... Alberta - A University of Alberta researcher in collaboration ... really does come with age, at least when it ... Dr. Florin Dolcos, assistant professor of psychiatry and neuroscience ... patterns that help healthy older people regulate and control ...
... 12 Not so long ago, any mention ... images of third-world,children with rickets and bone deformities. ... world to the developed, where Vitamin D deficiency,among ... rising to,astronomical proportions -- by some estimates, affecting ...
... Would Have Improved Benefits for Prevention, Mental,Health ... HARRISBURG, Pa., June 12 SUMMARY: ... critical legislation to protect and,improve Medicare for ... it. The,Medicare Improvements for Patients and Providers ...
... Serve Elective Cash Pay ... Patients, ... services for elective (cash pay) surgery, today,announced a leap forward in its ... bariatric surgeons, cash pay business.,Beginning July 1st, 2008, the BLISCare(SM) insurance policy ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
... MEDRAD, INC., has signed a,distribution and ... owned subsidiary of Siemens Medical Solutions USA, ... to inject Fluorodeoxyglucose,(FDG) for Positron Emission Tomography/Computed ... way. The partnership will leverage,MEDRAD,s soon to ...
Cached Medicine News:Health News:New research shows how aging brain brings a healthy dose of perspective 2Health News:Spotting Vitamin-D Deficiency in the Absence of Symptoms: ZRT Laboratory's New, One-of-a-Kind Blood Spot Test Answers the Call for Early Detection of Rapidly Rising D-Deficiencies 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 2Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 3Health News:Better Sleepers Are 'Successful Agers' 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Medicine Products: